NEFROLOGÍA

2001

Artículos

Alcázar JM, Marín R, Gómez Campderá F, Orte L, Rodríguez Jornet A, Mora Macía J, et al. Clinical characteristics of ischaemic renal disease. Nephrol Dial Transplant. 2001;16 Suppl 1:74–7

Alcazar JM, Rodicio JL; European Society of Hypertesnion. How to handle renovascular hypertension. J Hypertens. 2001;19(11):2109-11 [doi

Andrés A, Herrero JC, Praga M, González E, Morales JM, Ortiz M, et al. Double kidney transplant (dual) with kidneys from older donors and suboptimal nephronal mass. Transplant Proc. 2001;33(1-2):1166-7 [doi

Andrés A, Praga M, Ortuño T, Hernández E, Morales J. El donante marginal en el trasplante renal. Nefrologia. 2001;21 Suppl 4:104-10

Campo C, García Puig J, Segura J, Alcázar JM, García Robles R, Ruilope LM. Relación entre la gravedad de la hipertensión arterial esencial y la prevalencia de hiperuricemia. Med Clin (Barc). 2001;117(3):85-9

Campo C, Segura J, Fernández ML, Guerrero L, Christiansen H, Ruilope LM. A prospective comparison of four antihypertensive agents in daily clinical practice. J Clin Hypertens (Greenwich). 2001;3(3):139-44

Domínguez Gil B, Esforzado N, Muñoz MA, Andrés A, Rodicio JL, Bruguera M, et al. Trasplante renal utilizando riñones de donantes con serología positiva para el virus de la hepatitis C. Nefrologia. 2001;21 Suppl 4:119–23

Esmatjes E, Flores L, Íñigo P, Lario S, Ruilope LM, Campistol JM. Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant. 2001;16(Suppl 1):90-3 [doi

González E, Ortiz M, Praga M. Diabetes y riñón: Predictores de nefropatía y factores de progresión. Nefrologia. 2001;21 Suppl 3:46-51

Herrero JC, Morales E, Carreño A, Domínguez Gil B, González E, Ortiz M, Hernández E. Severe haemorrhage and retroperitoneal haematoma secondary to renal biopsy. Nephrol Dial Transplant. 2001;16(5):1078-9 [doi]

Latorre Ibarra A, Morales Ruiz E, Morales Cerdán JM, Manzanares Secades C. Concentraciones plasmáticas y depuración relativa de ácido micofenólico en pacientes trasplantados renales en un periodo de seguimiento de dos años.  Quim Clin. 2001;20(4):219-23

Marín R, Ruilope LM, Aljama P, Aranda P, Segura J, Díez J; Investigators of the ESPIRAL Study. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens. 2001;19(10):1871-6 [doi]

Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16 Suppl 1:121-4

Morales JM, Campistol JM, Andrés A, Domínguez Gil B, Esforzado N, Oppenheimer F, et al. Use of kidneys from anti-HCV positive donors. Transplant Proc. 2001;33(1-2):1776-7

Muñoz de Bustillo E, Benito A, Colina F, Andrés A, DomínguezGil B, Muñoz MA, et al. Fibrosing cholestatic hepatitis-like syndrome in hepatitis B virus-negative and hepatitis C virus-negative renal transplant recipients. Am J Kidney Dis. 2001;38(3):640-5

Praga M, Hernández E, Morales E, Campos AP, Valero MA, Martínez MA, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001;16(9):1790-8.

Praga M, Peñalver O, Camacho F. El paciente trasplantado. Nefrologia. 2001;21 Suppl 5:50–3

Rodicio JL, Alcázar JM. Hypertension in chronic renal failure. J Hypertens. 2001;19(11):2111-4

Ruilope LM. Kidney dysfunction: a sensitive predictor of cardiovascular risk. Am J Hypertens. 2001;14(6 Pt 2):213S-217S

Ruilope LM. Valsartan and the kidney: review of preclinical and clinical data. Adv Ther. 2001;18(2):57-66

Ruilope LM, Campo C, Segura J. The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue? Curr Hypertens Rep. 2001;3(5):419-21

Ruilope LM, Campo C, Segura J, Rodicio JL. What is the optimal blood pressure target in renal patients? Adv Nephrol Necker Hosp. 2001;31:43-53

Ruilope LM, García Puig J. Hyperuricemia and renal function. Curr Hypertens Rep. 2001;3(3):197-202

Ruilope LM, Rodicio JL. Renal participation in cardiovascular risk in essential hypertension. Blood Press. 2001;10(5-6):322-6

Ruilope LM, Rodicio JL. The kidney in arterial hypertension. Nephrol Dial Transplant. 2001;16 Suppl 1:50-2

Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001;12(2):218-25

Ruilope LM, Schiffrin EL. Blood pressure control and benefits of antihypertensive therapy: does it make a difference which agents we use? Hypertension. 2001;38(3 Pt 2):537-42

Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001;38(7):1782-7

Segura J, Campo C, Rodicio JL, Ruilope LM. ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. Hypertension. 2001;38(3 Pt 2):645-9

Segura de la Morena J, Campo Sien C, Fernández López ML, Guerrero Llamas L, García Vallejo O, Alcázar de la Ossa JM, et al. Control de la presión arterial: Experiencia de una Unidad monográfica de Hipertensión Arterial hospitalaria. Rev Clin Esp. 2001;201(6):308-14

Vázquez Pérez S, Aragoncillo P, De Las Heras N, Navarro Cid J, Cediel E, Sanz Rosa D, et al. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrol Dial Transplant. 2001;16(Suppl 1):40-4 [doi

Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhäger WH, et al.; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens. 2001;19(3):511-9 [doi

Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens. 2001;19(6):1149-59 [doi

.

2002

Artículos

Andrés A. Elderly donor kidney transplantation: arguments for double (dual) versus single kidney transplantation. Transplant Proc. 2002;34(1):358-9.

Andrés A, Cebrián M, Vázquez S, Vereda MS, Nuño K, Ortuño T, et al. Influence of expanding donor age on the allocation of kidneys for transplantation. Transplant Proc. 2002;34(1):15-6.

Andrés A, Herrero JC, González E, Morales E, Morales JM, Díaz R, et al. Long-term results of renal transplantation in elderly cadaver donor recipients 65 years old or older. Transplant Proc. 2002;34(1):356-7

Arroyo Bielsa A, Sánchez Guerrero A, Jiménez Gil R, Barrio Rodríguez C, Rodríguez de la Calle J, Porto Rodríguez J, et al. Clasificación y posibilidades terapéuticas de los aneurismas saculares de arteria renal. Angiologia. 2002;54(2):94-101

Campistol JM, Esforzado N, Morales JM, Barrera JM. Trasplante renal en pacientes virus de la hepatitis C positivos. Nefrologia. 2002;22 Suppl 5:62-6

Campo C, Segura J, Ruilope LM. Factors influencing the systolic blood pressure response to drug therapy. J Clin Hypertens (Greenwich). 2002;4(1):35-40.

Domínguez Gil B, Ortiz M, Sierra MP, Muñoz MA, Morales E, Andrés A, et al. Losartan reduces massive proteinuria in kidney transplant patients: a pilot study. Transplant Proc. 2002;34(1):368–9

García Tejada J, Tascón JC, Alcázar JM, Pindado C, Sanz AJ, Palacios J, et al. Estimulación bicameral en una paciente con miocardiopatía hipertrófica obstructiva refractaria y mala tolerancia a la ultrafiltración extracorpórea. Med Intensiva. 2002;26(2):75-8

Herrero JC, Andrés A, Leiva O, Díaz R, Polo G, Aguirre F, et al. Role of immunosuppressive treatments based on mycophenolate mofetil in posttransplantation renal surgical complications. Transplant Proc. 2002;34(1):96

Jiménez C, Moreno E, Andrés A. Indicaciones y resultados del trasplante de páncreas. Medifam. 2002;12(3):165-74

Jiménez C, Lumbreras C, Aguado JM, Loinaz C, Paseiro G, Andrés A, et al. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation. 2002;73(3):476-80

Jiménez C, Lumbreras C, Paseiro G, Loinaz C, Romano DR, Andrés A, et al. Treatment of mucor infection after liver or pancreas-kidney transplantation. Transplant Proc. 2002;34(1):82-3

Latorre A, Morales E, González E, Herrero JC, Ortiz M, Sierra P, et al. Clinical management of renal transplant patients with hepatitis C virus infection treated with cyclosporine or tacrolimus. Transplant Proc. 2002;34(1):63–4.

Marcén R, Morales JM, Fernández Juárez G, Andrés A, Pascual J, Rodicio JL, et al. Risk factors of ischemic heart disease after renal transplantation. Transplant Proc. 2002;34(1):394-5.

Morales E, Andrés A, González E, Herrero JC, Muñoz MA, Ortiz M, et al. Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy. Transplant Proc. 2002;34(1):73-4

Morales JM. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int Suppl. 2002;(82):S81-7

Morales JM, Campistol JM, Domínguez Gil B. Hepatitis C virus infection and kidney transplantation. Semin Nephrol. 2002;22(4):365-74

Morales JM, González Molina M, Campistol JM, Del Castillo D, Anaya F, Oppenheimer F, et al. Prevención del riesgo cardiovascular en el trasplante renal. Documento de consenso. Nefrologia. 2002;22 Suppl 4:35-56

Morales E, Martínez A, Sánchez Ayuso J, Gutiérrez E, Mateo S, Martínez MA, et al. Spontaneous improvement of the renal function in a patient with HIV-associated focal glomerulosclerosis. Am J Nephrol. 2002;22(4):369-71

Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andrés A, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant. 2002;2(5):436-42.

Muñoz MA, Andrés A, Gallego R, Morales E, Morales JM, Aguado JM, et al. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation. Transplant Proc. 2002;34(1):97

Praga M. Slowing the progression of renal failure. Kidney Int Suppl. 2002;(80):18-22

Praga M, Morales E. Renal damage associated with proteinuria. Kidney Int Suppl. 2002;(82):S42-6.

Ruilope LM. Long-term protection in at-risk hypertensive patients–a role for nifedipine GITS? Blood Press. 2002;11(2):106-9.

Ruilope LM. The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol. 2002;13 Suppl 3:S165-8.

Ruilope LM, Coca A, Banegas JR, Pablos JL, Luque M. Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity. Curr Hypertens Rep. 2002;4(4):261-4.

Ruilope LM, Coca A, Volpe M, Waeber B. ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am J Hypertens. 2002;15(4 Pt 1):367-71.

Ruilope LM, Luño J. Angiotensin blockade in type 2 diabetic renal disease. Kidney Int Suppl. 2002;(82):S61-3

Ruilope LM, Segura J. Cardiovascular therapy in patients with renal insufficiency. Cardiovasc Drugs Ther. 2002;16(6):497-501

Ruilope LM, Segura J. Renal protection by antihypertensive therapy. Curr Hypertens Rep. 2002;4(4):324-8.

Segura J, Campo C, Ruilope LM. Antihypertensive therapy and progression of renal failure. Saudi J Kidney Dis Transpl. 2002;13(3):266-72.

Segura J, Campo C, Ruilope LM. How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? J Clin Hypertens (Greenwich). 2002;4(5):332-6.

Segura J, Campo C, Ruilope LM. Proteinuria: an underappreciated risk factor in cardiovascular disease. Curr Cardiol Rep. 2002;4(6):458-62.

Torres A, Domínguez Gil B, Carreño A, Hernández E, Morales E, Segura J, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 2002;61(1):219-27.

.

2003

Artículos

Andrés A, Casal MC, Vereda MS, Vázquez S, Cebrián MP, Nuño E, et al. Double (dual) renal transplants for elderly recipients, using elderly cadaveric donors.  Dial Transplant. 2003;32(8):499-503,513

Andrés A, Revilla Y, Ramos A, González E, Vereda MS, Praga M, et al. Helical computed tomography angiography is the most efficient test to assess vascular calcifications in the iliac arterial sector in renal transplant candidates. Transplant Proc. 2003;35(5):1682-3.

Campo C, Ruilope LM, Segura J, Rodicio JL, García Robles R, García Puig J. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood Press. 2003;12(5-6):277-83.

Campo C, Segura J, Roldán C, Alcázar JM, Rodicio JL, Ruilope LM. Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension. Blood Press Suppl. 2003;2:16-21.

Espejo B, Herrero JC, Torres A, Martínez A, Gutiérrez E, Morales E, et al. Nefritis intersticial inmunoalérgica vs. ateroembolismo de colesterol. Características diferenciales. Nefrologia. 2003;23(2):125-30

Espejo B, Torres A, Valentín M, Bueno B, Andrés A, Praga M, et al. Obesity favors surgical and infectious complications after renal transplantation. Transplant Proc. 2003;35(5):1762-3.

García Vallejo O, Vicente Lozano J, Vegazo O, Jiménez Jiménez FJ, Llisterri Caro JL, Redón J, et al. Control de la presión arterial de los pacientes diabéticos en el ámbito de atención primaria. Estudio DIAPA. Med Clin (Barc). 2003;120(14):529-34

Herrero JC, Gutiérrez E, Martínez A, González E, Morales E, Muñoz MA, et al. Results of kidney transplantation in recipients over 70 years of age: experience at a single center. Transplant Proc. 2003;35(5):1675-6.

Morales E, Valero MA, León M, Hernández E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41(2):319-27.

Morales JM, Andrés A, Domínguez Gil B, Sierra MP, Arenas J, Delgado M, et al. Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation. Transplant Proc. 2003;35(3 Suppl):154S-156S.

Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant. 2003;18(9):1806-13.

Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14(6):1578-83.

Praga M, Torra R, Tazón B. Hematuria familiar benigna. Nefrologia. 2003;23 Suppl 1:40-5

Ruilope L. Proven benefits of angiotensin receptor blockers in the progression of renal disease. Eur Heart J Suppl. 2003;5(C):C9-C12

Rodicio JL. Forostat 2003: Multidisciplinary forum on statins. Proceedings of the 2nd Forostad, Rome, October 2003 – Foreword.  Drugs 2004;64(Suppl. 2)

Ruilope LM. Recent developments in the treatment of type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2003;17(2):151-8.

Ruilope L, Jäger B. Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003;4(1):107-14.

Ruilope LM. Lessons from trials in hypertensive type 2 diabetic patients. Curr Hypertens Rep. 2003;5(4):322-8.

Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther. 2003;25(12):3044-64.

Ruilope LM, Segura J, Campo C, Rodicio JL. Renal participation in cardiovascular risk in essential hypertension. Expert Rev Cardiovasc Ther. 2003;1(2):309-15.

Ruilope LM, Segura J, Schiffrin EL. ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients? J Renin Angiotensin Aldosterone Syst. 2003;4(2):74-9.

Sánchez R, Arroyo A, Gesto R, Fernández Reyes MJ, Mon C, Álvarez Ude F. Obstructive ARF caused by an inflammatory abdominal aortic aneurysm. Am J Kidney Dis. 2003;41(3):E9.

Segura J, Christiansen H, Campo C, Ruilope LM. How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria? Curr Hypertens Rep. 2003;5(5):426-9.

Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst. 2003;4(1):43-7.

.

2004

Artículos

Agabiti Rosei E, Rodicio JL. Olmesartan medoxomil: New signs in hypertension – Introduction. Clin Ther. 2004;26(Suppl. A):A1-A2

Andrés A, Mazuecos A, García García-Doncel A. A disproportionately greater body weight of the recipient in regards to the donor causes chronic graft nephropathy. A study of paired kidneys. Nephrol Dial Transplant. 2004;19 Suppl 3:iii21-5.

Andrés Belmonte A. Transplant strategies for diabetic renal patients. EDTNA ERCA J. 2004;30(3):157-62.

García Donaire JA, Manzanera MI, Valentín MO, Espejo B, Gutiérrez Martínez E, Praga M. Síndrome nefrótico recidivante por lesiones mínimas en un paciente diabético. Nefrologia. 2004;24(2):179-82.

García-Donaire JA, Núñez AG, Segura J, Ruilope LM. Cerebrovascular protection and antihypertensive therapy. Curr Opin Nephrol Hypertens. 2004;13(5):507-12

Gutiérrez E, González E, Morales E, Herrero JC, Manzanera MJ, García JA, et al. Efecto antiproteinúrico del bloqueo del sistema renina-angiotensina (SRA) en pacientes con presión arterial sistólica inferior o igual a 115 mmHg. Nefrologia. 2004;24(6):546-52

Gutiérrez E, González E, Hernández E, Herrero JC, Manzanera MJ, García JA, et al. Hiperfosforemia aguda tras preparación para colonoscopia. Nefrologia. 2004;24(3):283-7.

Morales JM. Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc. 2004;36(3):760-2.

Morales JM, Domínguez Gil B, Sanz Guajardo D, Fernández J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant. 2004;19 Suppl 3:iii72-6.

Noroña B, Valentín M, Gutiérrez E, Praga M. Tratamiento del síndrome nefrótico córtico-dependiente por lesiones mínimas con micofenolato mofetil. Nefrologia. 2004;24(1):79-82.

Ruilope LM. What is the impact of PRIME on real-life diabetic nephropathy? Int J Clin Pract. 2004;58(3):268-76.

Ruilope LM, Usan L, Segura J, Bakris GL. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004;22(1):217-22.

Ruilope LM, Volpe M. The case for blood pressure control in risk groups. Int J Clin Pract. 2004;58(9):844-9

Sánchez V, Delgado JF, Morales JM, Tello R, Gómez MA, Escribano P, et al. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc. 2004;36(9):2823-5

Segura J. Bloqueo del sistema renina-angiotensina. Nefrologia. 2004;24 Suppl(6):101-12, 187-235.

Segura J, Campo C, García Donaire JA, Ruilope LM. Development of chronic kidney disease in essential hypertension during long-term therapy. Curr Opin Nephrol Hypertens. 2004;13(5):495-500

Segura J, Campo C, Gil P, Roldán C, Vigil L, Rodicio JL, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol. 2004;15(6):1616-22.

Segura J, Campo C, Roldán C, Christiansen H, Vigil L, García Robles R, et al. Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. J Am Soc Nephrol. 2004;15 Suppl 1:S37-42.

Segura J, Campo C, Ruilope LM. Chronic kidney disease and global cardiovascular risk in essential hypertension. Minerva Med. 2004;95(5):375-83

Segura J, Campo C, Ruilope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int Suppl. 2004;66(92):S45-S49

Segura J, Ruilope LM, Rodicio JL. Microalbuminuria. Clin Exp Hypertens. 2004;26(7-8):701-7.

Segura J, Ruilope LM, Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. J Hypertens. 2004;22(9):1635-9.

Segura de la Morena J, García Donaire JA, Ruilope Urioste LM. Relevancia de la insuficiencia renal en el pronóstico cardiovascular d elos pacientes con hipertensión arterial esencial. Med Clin (Barc). 2004;123(4):143-8.

Sierra C, Ruilope LM. Novel antihypertensive agents. Expert Opin Investig Drugs. 2004;13(8):987-98.

Valentín M, Bueno B, Gutiérrez E, Martínez A, González E, Espejo B, et al. Glomerulonefritis membranoproliferativa hipocompleméntica asociada a tiroiditis autoinmune. Nefrologia. 2004;24 Suppl 3:43-8.

.

2005

Artículos

Andrés A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol. 2005;56(1):71-85.

Carlavilla A, Gutiérrez E, Ortuño T, Morales E, González E, Praga M. Relapse of lupus nephritis more than 10 years after complete remission. Nephrol Dial Transplant. 2005;20(9):1994-8.

Campo C, Roldán C, Segura J. Prevención primaria de la HTA: ¿Posibilidad real o utopía? Detección precoz de la HTA. Nefrologia. 2005;25 Suppl 4:7-12.

Campo C, Saavedra J, Segura J, Roldán C, Ruilope LM, Parati G. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med. 2005;96(5):365-71.

García Donaire JA, Acevedo M, Gutiérrez MJ, Manzanera MJ, Oliva E, Gutiérrez E, et al. Tacrolimus as basic immunosuppression in pregnancy after renal transplantation. A single-center experience. Transplant Proc. 2005;37(9):3754-5.

García Donaire JA, Alcázar JM. Ischemic nephropathy: detection and therapeutic intervention. Kidney Int Suppl. 2005;(99):S131-6.

García Donaire JA, Segura J, Ruilope LM. An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy. Expert Opin Pharmacother. 2005;6(9):1587-96.

González E, Gutiérrez E, Hernández Y, Roselló G, Gutiérrez MJ, Martínez EG, et al. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function. Transplant Proc. 2005;37(9):3736-7.

González E, Gutiérrez E, Morales E, Hernández E, Andrés A, Bello I, et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int. 2005;68(1):263-70.

González de la Aleja J, Posada IJ, Sepúlveda Sánchez JM, Galán L, Conde Gallego E, Ricoy Campo JR. Panencefalitis esclerosante subaguda de comienzo en la edad adulta. Hallazgos clínicopatológicos. Rev Neurol. 2005;40(12):729-32.

Gutiérrez MJ, Acebedo Ribó M, García Donaire JA, Manzanera MJ, Molina A, González E, et al. Pregnancy in renal transplant recipients. Transplant Proc. 2005;37(9):3721-2.

Gutiérrez E, González E, Morales E, Herrero JC, Manzanera MJ, García JA, et al. Efecto antiproteinúrico del bloqueo del sistema renina-angiotensina (SRA) en pacientes con presión arterial sistólica inferior o igual a 115 mmHg. Nefrologia. 2004;24(6):546-52.

Manzanera MJ, Gutiérrez E, Domínguez-Gil B, García JA, González E, Praga M. Hemorragia digestiva por angiodisplasia en pacientes en hemodiálisis. Tratamiento con estrógenos conjugados. Nefrologia. 2005;25(4):412–5.

Morales JM. Cardiovascular risk profile in patients treated with sirolimus after renal transplantation. Kidney Int. 2005;67(Suppl. 93):S69-S73

Morales JM. Does time of onset of therapy alter the protective cardiovascular effect of fluvastatin after renal transplantation? Nat Clin Pract Nephrol. 2005;1(2):78-9.

Morales JM. Immunosuppressive treatment and progression of histologic lesions in kidney allografts. Kidney Int Suppl. 2005;(99):S124-30.

Morales JM. Post-transplantation hypertension. Saudi J Kidney Dis Transpl. 2005;16(4):443-52

Morales JM, Andrés A, Domínguez Gil B, Arriola M, Gutiérrez MJ, Hernández E, et al. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients. Transplant Proc. 2005;37(9):3738-42.

Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, et al. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. Transplant Proc. 2005;37(2):693-6.

Morales JM, Domínguez Gil B. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. J Hypertens. 2005;23(9):1609-16.

Moreno Cuerda VJ, Aguado JM, Morales M, Andrés A, Morales JM, López Medrano F, et al. Is double renal transplantation a risk factor for cytomegalovirus disease? Transplant Proc. 2005;37(9):3764-5.

Nungaray N, Arriola M, Gutiérrez MJ, Oliva E, Hernández E, González E, et al. Rapamycin at six years can exhibit normal renal function without proteinuria or neoplasia after renal transplantation. A single-center experience. Transplant Proc. 2005;37(9):3727-8.

Praga M. Prevención de la insuficiencia rebnal más allá del control de la HTA y d ela diabetes mellitus. Nefrologia. 2005;25 Suppl 4:78-81.

Praga M. Therapeutic measures in proteinuric nephropathy. Kidney Int Suppl. 2005;(99):S137-41.

Praga M. Tratamiento de la glomeruloesclerosis segmentaria y focal. Nefrologia. 2005;25(6):612-4, 616-8, 620-1.

Praga M. Tratamiento de la glomerulonefritis membranosa. Nefrologia. 2005;25(5):467-70, 472-4.

Ruilope LM. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabetol. 2005;42 Suppl 1:S33-41.

Ruilope LM. The launch of the Renin Academy. J Renin Angiotensin Aldosterone Syst. 2005;6(2):49.

Ruilope LM, Heintz D, Brandão AA, Stolt P, Kandra A, Santonastaso M, et al. 24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study. Blood Press Monit. 2005;10(2):85-91.

Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27(5):578-87.

Ruilope LM, Segura J. Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension. Clin Ther. 2005;27(10):1658-68

Ruilope LM, Volpe M. Treating hypertension with angiotensin II receptor blockers: A step ahead of blood pressure reduction?  High Blood Press Cardiovasc Prev. 2005;12(1):9-15

Segura J, Campo C, Ruilope LM. Influence of chronic kidney disease development and renin-angiotensin system inhibition on cardiovascular prognosis. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(1):55-60.

Segura J, Campo C, Ruilope LM, Rodicio JL. Do we need to target “prediabetic” hypertensive patients? J Hypertens. 2005;23(12):2119-25.

Segura J, García Donaire JA, Ruilope LM. Calcium channel blockers and renal protection: insights from the latest clinical trials. J Am Soc Nephrol. 2005;16 Suppl 1:S64-6

Segura J, Ruilope LM. Cronoterapia antihipertensiva y morbimortalidad cardiovascular. Med Clin Monogr. 2005;6(2):65-70

Segura J, Ruilope LM. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. Fundam Clin Pharmacol. 2005;19(4):429-37

.

2006

Artículos

Andrés A, Morales E, Morales JM, Bosch I, Campo C, Ruilope LM, et al. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study. Transplant Proc. 2006;38(8):2419-23

Barrios V, Escobar C, Calderón A, Navarro A, Ruilope LM. The effectiveness and tolerability of lercanidipine is independent of body mass index or bodyfatpercent. The LERZAMIG study.  Br J Cardiol. 2006;13(6):434-40

Díaz Pedroche C, Lumbreras C, San Juan R, Folgueira D, Andrés A, Delgado J, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation. 2006;82(1):30-5.

Fernández ML, Guerrero L, Segura J. Cronoterapia en hipertensión. Rev Enferm. 2006;29(5):26-30.

García Donaire JA, Ruilope LM. Spotlight on renin: cardiovascular outcomes in chronic kidney disease and suppression of the renin-angiotensin system. J Renin Angiotensin Aldosterone Syst. 2006;7(1):56-8

Manrique A, Jiménez C, Herrero ML, Meneu JC, Abradelo M, Moreno A, et al. Pancreas preservation with the University of Wisconsin versus Celsior solutions. Transplant Proc. 2006;38(8):2582-4

Morales JM. Introducción: Importancia clínica de la agresión inmunológica del injerto después del trasplante renal. Nefrologia. 2006;26(Suppl 7):1-2.

Morales JM. Neoplasias y trasplante. Nefrologia. 2006;26(Suppl 2):12-20.

Morales JM, Domínguez Gil B. Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation. J Am Soc Nephrol. 2006;17(12 Suppl 3):S296-303.

Morales JM, Domínguez Gil B, Gutiérrez MJ. Impacto de la inmunosupresión en el perfil de riesgo cardiovascular después del trasplante renal. Nefrologia. 2006;26(2):181-94.

Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006;15(5):481-6.

Praga M, Morales E. Weight loss and proteinuria. Contrib Nephrol. 2006;151:221-9

Ruilope L. Introduction.  J Renin Angiotensin Aldosterone Syst. 2006;7(Suppl. 2):S1-S2

Ruilope LM, Mount DB. Editorial introductions. Curr Opinion Nephrol Hypertens. 2006;15(5):vii

Ruilope LM, Segura J. Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax). J Hypertens Suppl. 2006;24(3):S9-12

Ruilope LM, Segura J, Tocci G, Volpe M. Treatment of high-riskhypertensivepatients: Unresolvedissuesrevised by staging the risk. High Blood Press Cardiovasc Prev. 2006;13(1):13-19

Segura J, García Donaire JA, Praga M, Ruilope LM. Chronic kidney disease as a situation of high added risk in hypertensive patients. J Am Soc Nephrol. 2006;17(4 Suppl 2):S136-40.

Segura J, Roldán C, García Donaire JA, Ruilope LM. Prediabetes and cardiovascular risk in hypertensive patients. Curr Hypertens Rep. 2006;8(2):97-100.

Segura J, Ruilope LM. Antihypertensive therapy in patients with metabolic syndrome. Curr Opin Nephrol Hypertens. 2006;15(5):493-7.

.

2007

Artículos

Armario P, Segura J, Vigil L, Galera J, Parody E, Ruilope LM. Factores y causas de mal control y estrategias de corresponsabilidad médico-paciente en el control de la hipertensión. Resultados de los estudios COROPINA y COREVALUA del programa CORRESPONDE. Hipertension. 2007;24(3):93-100

Banegas JR, De la Sierra A, Segura J, De la Cruz JJ, Ruilope LM. Response to out-of-office bloodpressure control amongtreatedsubjects.  Hypertension. 2007;49(6):e42

Banegas JR, De la Sierra A, Segura J, Sobrino J, Ruilope LM. Response to is siesta maskingmaskedhypertension? Hypertension. 2007;49(4):e26

Banegas JR, De la Sierra A, Sobrino J, Segura J, Ruilope LM. Response to influence of siesta in the estimation of blood pressure control in patients with hypertension. Hypertension. 2007;50(2):e15

Barrios V, Escobar C, Navarro Á, Calderón A, Ruilope LM. Antihypertensiveeffectiveness of lercanidipineadministeredusing an electronicpillboxcompared with usual care in a cohort of mild-to-moderatelyhypertensivepatients: The ELECTRA study. Therapy. 2007;4(4):433-40

Burnier M, Zanchi A, Hilfiker-Kleiner D, Drexler H, Rubattu S, Ruilope LM, et al. Highlights from internationalcongress: The X forum on the renin-angiotensinsystem, Capri, April 2007. High Blood Press Cardiovasc Prev. 2007;14(2):103-10

Coca A, Bertomeu V, Dalfó A, Esmatjes E, Guillén F, Guerrero L, et al. Automedida de la presión arterial. Documento de Consenso Español 2007. Hipertension. 2007;24(2):70-83

Coca A, Bertomeu V, Dalfó A, Esmatjes E, Guillén F, Guerrero L, et al. Automedida de la presión arterial. Documento de Consenso Español 2007. Rev Esp Geriatr Gerontol. 2007;42(2):115-28

De la Sierra A, Ruilope LM. Are calciumchannelblockersfirst-line drugs for the treatment of hypertension and cardiovascular disease? Curr Hypertens Rev. 2007;3(1):9-13

De la Sierra A, Ruilope LM. Inhibidores de la renina. Una nueva forma de supresión farmacológica del sistema renina-angiotensina. Med Clin Monogr. 2007;8(5):1-3

Domínguez Gil B, Esforzado N, Campistol JM, Andrés A, Morales JM. Use of hepatitis C-positive donors for kidney transplantation. Transplant Rev. 2007;21(4):195-203

García Donaire JA, Ruilope LM. Angiotensin receptor blockade in diabetic renal disease–focus on candesartan. Diabetes Res Clin Pract. 2007;76(Suppl 1):S22-30.

García Donaire JA, Ruilope LM. Trandolapril/verapamil combination in hypertensive diabetic patients. Vasc Health Risk Manag. 2007;3(1):77-82.

García Donaire JA, Segura J, Ruilope LM. Clinical trials in nephrology: success or failure. Curr Opin Nephrol Hypertens. 2007;16(2):59-63.

Gutiérrez E, Andrés A. Selection of donor and organ viability criteria: expanding donation criteria. J Ren Care. 2007;33(2):83-8.

Gutiérrez E, González E, Hernández E, Morales E, Martínez MA, Usera G, et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol. 2007;2(1):51-7.

Gutiérrez E, Morales E, Gutiérrez Martínez E, Manzanares MJ, Rosello G, Mérida E, et al. Glomerulopatías asociadas a la infección por VIH una perspectiva española. Nefrologia. 2007;27(4):439-47

Gutiérrez Millet V, Martínez Rincón C, Rodríguez Á. Complicaciones nutricionales de la cirugía bariátrica en la obesidad mórbida. Rev Esp Obes. 2007;5(6):388-93

López Medrano F, Aguado JM, Lizasoaín M, Folgueira D, Juan RS, Díaz Pedroche C, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation. 2007;84(7):851-6.

Manzanera Escribano MJ, Morales Ruiz E, Odriozola Grijalba M, Gutiérrez Martínez E, Rodríguez Antolín A, Praga Terente M. Acute renal failure due to interstitial nephritis after intravesical instillation of BCG. Clin Exp Nephrol. 2007;11(3):238-40.

Praga M, Barrio V, Juárez GF, Luño J, Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924-30

Roldán Suárez C, Pablo Tomás J, García Donaire JA, Segura de la Morena J. Importancia de la prevención de la fibrilación auricular en el paciente hipertenso. Hipertension. 2007;24(4):164-71

Ruilope LM. Comentario sobre las nuevas guías europeas de hipertensión arterial. Hipertension. 2007;24(6):229-30

Ruilope LM. Renal AT 1 receptors and hypertension. Nephrol Dial Transplant. 2007;22(8):2136-7.

Ruilope LM, Kirwan BA, De Brouwer S, Danchin N, Fox KAA, Wagener G, et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens. 2007;25(8):1711-8.

Ruilope L, Kjeldsen SE, de la Sierra A, Mancia G, Ruggenenti P, Stergiou GS, et al. The kidney and cardiovascular risk–implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007;16(2):72-9.

Ruilope LM, Redón J, Schmieder R. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme. Vasc Health Risk Manag. 2007;3(1):1-9.

Ruilope LM, Zanchetti A, Julius S, McInnes GT, Segura J, Stolt P, et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens. 2007;25(7):1473-9.

Segura J, Banegas JR, García Donaire JA, Rodríguez Artalejo F, De la Cruz JJ, Praga M, et al. Should hypertension guidelines be changed for hypertensive patients with the metabolic syndrome? J Clin Hypertens (Greenwich). 2007;9(8):595-600.

Segura J, García Donaire JA, Ruilope LM. Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy? Curr Opin Nephrol Hypertens. 2007;16(5):422-6.

Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr. 2007;10(10A):1151-5

Segura de la Morena J. Antagonistas de los receptores de la angiotensina y protección frente al desarrollo de enfermedad renal. Hipertension. 2007;24(Supl. 1):17-24

Segura de la Morena J. Papel del bloqueo del sistema renina-angiotensina con inhibidores directos de la renina en la protección frente a la lesión renal. Med Clin Monogr. 2007;8(5):22-6

Segura de la Morena J, Ruilope Urioste LM. Nexo entre las alteraciones del metabolismo hidrocarbonado, morbilidad y mortalidad en diabetes tipo 2. Med Clin Monogr. 2007;8(1):18-22

.

2008

Artículos

Alcázar JM, Arenas MD, Álvarez Ude F, Virto R, Rubio E, Maduell F, et al. Resultados del proyecto de mejora de la calidad de la asistencia en hemodiálisis: Estudio multicéntrico de indicadores de calidad de la Sociedad Española de Nefrología (SEN). Nefrologia. 2008;28(6):597-606.

González E, Gutiérrez E, Galeano C, Chevia C, De Sequera P, Bernis C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940-6

Gorostidi M, Segura J. Diabetes: Nuevas aproximaciones a un problema clásico. Hipertension. 2008;25(3):91-3

Jiménez C, Manrique A, Morales JM, Andrés A, Ortuño T, Abradelo M, et al. Influence of dialysis modality on complications and patient and graft survival after pancreas-kidney transplantation. Transplant Proc. 2008;40(9):2999-3000

López Medrano F, García Bravo M, Morales JM, Andrés A, San Juan R, Lizasoaín M, et al. Urinary tract infection due to Corynebacterium urealyticum in kidney transplant recipients: an underdiagnosed etiology for obstructive uropathy and graft dysfunction-results of a prospective cohort study. Clin Infect Dis. 2008;46(6):825-30.

Morales E, Gutiérrez Solís E, Gutiérrez E, González R, Martínez MA, Praga M. Malignant hypertension in HIV-associated glomerulonephritis. Nephrol Dial Transplant. 2008;23(12):3901-7.

Morales JM, Grinyó JM, Campistol JM, García Martínez J, Arias M, Paul J, et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation. 2008;86(4):620-2.

Morales JM, Marcén R, Andrés A, Molina MG, Castillo DD, Cabello M, et al. Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int Suppl. 2008;(111):S94-9

Morales Ruiz E. Trasplante renal anticipado. Nefrologia. 2008;28(Suppl 3):123-8

Morales Ruiz E, Praga Terente M. Relación entre obesidad y desarrollo de insuficiencia renal. Hipertension. 2008;25(2):61-9

Praga M. Response to ‘Steroids in acute interstitial nephritis’. Kidney Int. 2008;74(7):972-3

Praga M. Response to ‘Steroid treatment of drug-induced acute interstitial nephritis’. Kidney Int. 2008;74(10):1360-1

Ruilope LM. Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin. 2008;24(5):1285-93.

Ruilope LM. Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension. Vasc Health Risk Manag. 2008;4(6):1237-48

Ruilope LM. New ADVANCEs in guidelines. J Hypertens Suppl. 2008;26(2):S16-8

Ruilope LM. The clinical significance of blood pressure lowering treatment: First-line drug choice is important – The pro position. High Blood Press Cardiovasc Prev. 2008;15(3):113-5

Ruilope LM, Burnier M, Muszbek N, Brown RE, Keskinaslan A, Ferber P, et al. Public health value of fixed-dose combinations in hypertension. Blood Press Suppl. 2008 Jun;1:5-14.

Ruilope LM, Després JP, Scheen A, Pi Sunyer X, Mancia G, Zanchetti A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens. 2008;26(2):357-67.

Ruilope LM, Jakobsen A, Heroys J, Ralph A, Rees T, Shaw M. Prospects for renovascular protection by more aggressive renin-angiotensin system control. Medscape J Med. 2008;10 Suppl:S5.

Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21(5):500-8.

Ruilope LM, Segura J. The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy. Clin Exp Hypertens. 2008;30(5):397-414

Ruilope LM, Zanchetti A, Julius S, McInnes GT, Segura J, Hua TA, Weber MA, Jamerson K. Reply. J Hypertens. 2008;26(1):154

Segura J, Roldán C, Galera J, Naval J. What Do Spanish physicians believe and expect about telemedicine? Results of a Delphi-based survey. Telemed J E Health. 2008;14(1):42-8.

Segura J, Ruilope LM. Hyperkalemia risk and treatment of heart failure. Heart Fail Clin. 2008;4(4):455-64.

Segura J, Ruilope LM. New guidelines of the European Society of Hypertension. Curr Hypertens Rep. 2008;10(5):337-8

Segura de la Morena J. Nuevas evidencias en protección vascular. Papel del bloqueo de los receptores de la angiotensina II. Med Clin Monogr. 2008;9(5):8-12

Torres J, Aguado JM, San Juan R, Andrés A, Sierra P, López Medrano F, et al. Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation. Transpl Int. 2008;21(9):873-8.

.

2009

Artículos

Alexandru S, González E, Grande C, Hernández A, Morales E, Praga M, et al. Monotherapy rapamycin in renal transplant recipients with lymphoma successfully treated with rituximab. Transplant Proc. 2009;41(6):2435-7.

Andrés A, Budde K, Clavien PA, Becker T, Kessler M, Pisarski P, et al. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. Transplantation. 2009;88(9):1101-8.

Andrés A, Marcén R, Valdés F, Plumed JS, Solà R, Errasti P, et al. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clin Transplant. 2009;23(1):23-32.

Andrés A, Morales E, Vázquez S, Cebrián MP, Nuño E, Ortuño T, et al. Lower rate of family refusal for organ donation in non-heart-beating versus brain-dead donors. Transplant Proc. 2009;41(6):2304-5.

Andrés A, Polanco N, Cebrián MP, Sol Vereda M, Vázquez S, Nuño E, et al. Kidneys from elderly deceased donors discarded for transplantation. Transplant Proc. 2009;41(6):2379-81

Banegas JR, Messerli FH, Waeber B, Rodríguez Artalejo F, De la Sierra A, Segura J, et al. Discrepancies between office and ambulatory blood pressure: clinical implications. Am J Med. 2009 Dec;122(12):1136-41 [doi

Blanco M, Medina J, González E, Domínguez M, Rodríguez A, Pamplona M, et al. Third Kidney Transplantation: A Permanent Medical-Surgical Challenge. Transplant Proc. 2009;41(6):2366–9.

Blanco M, Medina J, Pamplona M, Miranda N, González E, Aguirre JF, et al. Outcome of Renal Transplantation in Adult Patients With Augmented Bladders. Transplant Proc. 2009;41(6):2382–4

Castillo Rama M, Grande C, Martínez Sánchez P, Olavarría E, Marín D, Paz-Artal E, et al. Remisión molecular de una leucemia mieloide crónica en un paciente con segundo trasplante renal y hepatitis. Nefrologia. 2009;29(6):604-7

De la Sierra A, Banegas JR, Redón J, Segura J, Gorostidi M, Ruilope LM. Response to nondipping in patients with hypertension. Hypertension. 2009;53(5):e36

Domínguez Gil B, Morales JM. Transplantation in the patient with hepatitis C. Transpl Int. 2009 Dec;22(12):1117-31 [doi

Fernández Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N, et al.; Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009;4(8):1317-23 [doi

Fernández Ruiz M, López Medrano F, García Sánchez L, García Reyne A, Solo TO, Sanz Sanz F, et al. Successful management of tunneled hemodialysis catheter-related bacteremia by Leclercia adecarboxylata without catheter removal: report of two cases. Int J Infect Dis. 2009;13(6):e517-8

Fernández Ruiz M, López Medrano F, Gutiérrez E, Aguado JM. Complex visual hallucinations induced by voriconazole. Med Clin. 2009;133(4):156–7

García Donaire JA, Cerezo C, Ruilope LM. Efectos renales de los antagonistas del calcio.  Hipertens Riesgo Vasc. 2009;26(3):116-20

García Martín F, Huerta Arroyo A, Alcázar de la Ossa JM, Praga Terente M. Hiperamilasemia en un paciente con mieloma múltiple en hemodiálisis. Nefrologia. 2009;29(1):93-4.

González E, Andrés A, Polanco N, Hernández A, Morales E, Hernández E, et al. Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation. Transplant Proc. 2009;41(6):2332-3.

González E, Praga M, Grupo Madrileño de Nefritis Intersticiales. ¿Cuándo tratar con esteroides a los pacientes con nefritis intersticial aguda por fármacos? Nefrologia. 2009;29(2):95-8.

Gutiérrez MJ, González E, Andrés A, Morales JM. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction. Transplant Proc. 2009;41(6):2348-50.

Gutiérrez MJ, González P, Delgado I, Gutiérrez E, González E, Siqueira RC, et al. Renal allograft function and cardiovascular risk in recipients of kidney transplantation after successful pregnancy. Transplant Proc. 2009;41(6):2399-402.

Gutiérrez Sánchez MJ, Morales Cerdán JM, Belmonte AA. Optimization of immunosuppression by switching from azathioprine to enteric-coated mycophenolate sodium in stable kidney transplant patients. Transplant Proc. 2009;41(6):2320-2

Hernández D, Sánchez-Fructuoso A, González Posada JM, Arias M, Campistol JM, Rufino M, et al. A novel risk score for mortality in renal transplant recipients beyond the first posttransplant year. Transplantation. 2009;88(6):803–9

Huerta A, Segovia B, Hernández A, Morales E, González J, Mérida E, et al. When the finding of glomerular fibrils in patients with nephrotic syndrome leads to an erroneous diagnosis. NDT Plus. 2009;2(1):63-6

Juan RS, Yebra M, Lumbreras C, López Medrano F, Lizasoaín M, Meneu JC, et al. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients. Clin Transplant. 2009;23(5):666-71

Llisterri JL, Alonso FJ, Gorostidi M, Sierra C, De la Sierra A, Banegas JR, et al. Diferencias entre el control clínico y ambulatorio de la hipertensión arterial en pacientes muy ancianos. Proyecto CARDIORISC-MAPAPRES. Med Clin. 2009;133(20):769-76. Erratum in: Med Clin. 2010;135(7):342

Llisterri JL, Alonso FJ, Gorostidi M, Sierra C, De la Sierra A, Banegas JR, et al. Erratum: Fe de errores de «diferencias en el grado de control de la hipertensión arterial según métodos de medida en pacientes muy ancianos. Proyecto CARDIORISC MAPAPRES». Med Clin. 2010;135(7):342. Erratum for: Med Clin. 2009;133(20):769-76

López Medrano F, Rueda B, Lizasoaín M, Juan RS, Folgueira D, Andrés A, et al. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients. Transplant Infect Dis. 2009;11(5):400-4

López Pintor RM, Hernández G, De Arriba L, Morales JM, Jiménez C, De Andrés A. Amlodipine and nifedipine used with cyclosporine induce different effects on gingival enlargement. Transplant Proc. 2009;41(6):2351-3

López-Pintor RM, Hernández G, De Arriba L, Morales JM, Jiménez C, de Andrés A. Oral Ulcers During the Course of Cytomegalovirus Infection in Renal Transplant Recipients. Transplant Proc. 2009;41(6):2419–21.

Mancia G, Laurent S, Agabiti Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force documental. Blood Press. 2009;18(6):308-47

Martín Navarro J, Ortega M, Gutiérrez MJ, García Martín F, Alcázar JM, Morales JM, et al. Survival of patients older than 60 years with kidneys transplanted from Spanish expanded criteria donors versus patients continued on hemodialysis. Transplant Proc. 2009;41(6):2376-8

Medina Polo J, Morales JM, Blanco M, Aguirre JF, Andrés A, Díaz R, et al. Urological Complications After Simultaneous Pancreas-Kidney Transplantation. Transplant Proc. 2009;41(6):2457–9

Mérida E, Rodríguez A, Hernández G, Huerta A, González J, Hernández A, et al. Renal transplantation in emigrants from Africa in Spain: similar results but different infectious profile compared with Spanish people. Transplant Proc. 2009;41(6):2363-5

Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, et al. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. Transplant Proc. 2009;41(6):2339-44.

Morales E, Huerta A, Gutiérrez E, Gutiérrez Solís E, Segura J, Praga M. Efecto antiproteinúrico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. ¿Cuál es la opción terapéutica más eficaz? Nefrologia. 2009;29(5):421-9.

Muñoz R, Ramírez E, Fernández I, Martín A, Romero M, Romero E, et al. Correlation between fibroscan, liver biopsy, and clinical liver function in patients with hepatitis C virus infection after renal transplantation. Transplant Proc. 2009;41(6):2425-6.

Polanco N, Hernández E, González E, Gutiérrez Martínez E, Bello I, Gutiérrez Millet V, et al. Deterioro de función renal Inducido por fibratos. Nefrologia. 2009;29(3):208-13

Ramírez E, Morales JM, Lora D, Mellado M, Cevey M, Alfaro FJ, et al. Peripheral blood regulatory T cells in long-term kidney transplant recipients. Transplant Proc. 2009;41(6):2360-2.

Ramírez E, Serrano A, García F, Alfaro FJ, Pérez V, Paz-Artal E, et al. Prospective study on autoantibodies against apolipoprotein H (beta2GPI) in several clinical parameters from patients with terminal renal failure and functioning renal transplants. Transplant Proc. 2009;41(6):2370-2

Ruilope LM. Raas inhibition and renoprotection – Are they doing it beyond blood pressure lowering. Am J Hypertens. 2009;22(Suppl. 1):5

Ruilope LM, Segura J. Kidney protection: a key target in the management of patients with diabetes. J Hypertens Suppl. 2009;27(1):S15-8

Rydén L, Waeber B, Ruilope LM, Mancia G, Volpe M, Holzgreve H, et al. Manažment pacientov s diabetom 2. Typu a hypertenziou – Príliš neskoro a málo účinne: Návrh zlepšenia. Kardiologia. 2009;18(6):286–93

Sánchez Fructuoso A, Ruiz JC, Rengel M, Andrés A, Morales JM, Beneyto I, et al. Use of Mycophenolate Sodium in Stable Renal Transplant Recipients in Spain: Preliminary Results of the MIDATA Study. Transplant Proc. 2009;41(6):2309–12

Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutiérrez Solis E, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol. 2009;4(6):1083-8 [doi

Segura J, Ruilope LM. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. Lancet. 2009;374(9683):26

Segura J, Ruilope LM. Should diuretics always be included as initial antihypertensive management in early-stage CKD? Curr Opin Nephrol Hypertens. 2009;18(5):392-6

Segura J, Ruilope LM. Treatment of prehypertension in diabetes and metabolic syndrome: what are the pros? Diabetes Care. 2009;32(Suppl 2):S284-9

Waeber B, De la Sierra A, Ruilope LM. The ADVANCE trial: Clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2009;9(5):283-91

Waeber B, Feihl F, Ruilope LM. Fixed-dose combinations as initial therapy for hypertension: A review of approved agents and a guide to patient selection. Drugs. 2009;69(13):1761-76

Congresos

De La Rosa F, Rodríguez A, Villacampa F, Aguirre F, Pamplona M, Blanco M, et al. Renal transplant in extremely old receptors. Urology. 2009;74(4):S54–5 [Congress of the Societe Internationale d’Urologie (30. Shanghai. 2009)]

De La Sierra A, Banegas JR, De La Cruz JJ, Segura J, Gorostidi M, Vinyoles E, et al. Prevalence and clinical features of isolated clinical hypertension and dipping profile in a large cohort of untreated hypertensive subjects. Hypertension. 2009;54(4):e60 [High Blood Pressure Research Conference (63. Chicago. 2009)]

Medina Polo J, Morales J, Aguirre J, Díaz R, Pamplona M, Passas J, et al. Urological complications after simultaneous pancreaskidney transplantation. Urology. 2009;74(4):S53 [Congress of the Societe Internationale d’Urologie (30. Shanghai. 2009)]

.

2010

Artículos

Andrés A. Indicaciones y contraindicaciones de la donación renal de vivo. Nefrologia. 2010;30(Suppl 2):30-8.

Andrés A, Delgado Arranz M, Morales E, Dipalma T, Polanco N, Gutiérrez Solís E, et al. Extended-release tacrolimus therapy in de novo kidney transplant recipients: single-center experience. Transplant Proc. 2010;42(8):3034-7.

Banegas JR, De la Sierra A, Segura J, Ruilope LM. Office vs. ambulatory control of hypertension in CHD patients. Int J Cardiol. 2010;145(2):352.

Benito León J, Louis ED, Rivera Navarro J, Medrano MJ, Vega S, Bermejo Pareja F. Low morale is associated with increased risk of mortality in the elderly: a population-based prospective study (NEDICES). Age Ageing. 2010;39(3):366-73

Fernández L, Guerrero L, Segura J, Gorostidi M. Papel del personal de enfermería en el control de la hipertensión arterial y en la investigación cardiovascular. Hipertens Riesgo Vasc. 2010;27(Supl 1):41-52

García Donaire JA, Ruilope LM. Multiple action fixed combination. Present or future? Fundam Clin Pharmacol. 2010;24(1):37-42.

García Donaire JA, Ruilope LM. Recent advances in the management of hypertension. F1000 Med Rep. 2010;2:19

García Donaire JA, Ruilope LM. Systolic pressure, diastolic pressure, or pulse pressure as a cardiovascular risk factor in renal disease. Curr Hypertens Rep. 2010;12(4):307-12.

González R, Morales E, Segura J, Ruilope LM, Praga M. Long-term renal survival in malignant hypertension. Nephrol Dial Transplant. 2010;25(10):3266-72.

González Monte E, Andrés A, Polanco N, Toribio MJ, Santana R, Gutiérrez Martínez E, et al. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months. Transplant Proc. 2010;42(8):2899-901

González Monte E, Delgado I, Polanco N, Hernández E, Dipalma T, Hernández A, et al. Results of a living donor kidney promotion program. Transplant Proc. 2010;42(8):2837-8

Gorostidi M, Ruilope LM. Aportaciones del proyecto CARDIORISC. Introducción. Hipertens Riesgo Vasc. 2010;27(Supl 1):1-3

Gorostidi M, Segura J, de la Sierra A. Hipertensión arterial nocturna. Hipertens Riesgo Vasc. 2010;27(Si¡upl 1):26-33

Gustafsson F, Segura J, Ruilope LM. How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease? J Hypertens. 2010;28(8):1595-8

Gutiérrez Solís E, Morales E, Rodríguez Jornet A, Andreu FJ, Rivera F, Vozmediano C, et al. Enfermedad renal ateroembólica: Un análisis de los factores clínicos y terapéuticos que influyen en su evolución. Nefrologia. 2010;30(3):317-23

Lumbreras Fernández J, Cruz Rojo J, Íñigo Martín G, Muley Alonso R, Vara Martín J. Síndrome hemolítico-urémico: afectación renal a largo plazo. Anales de Pediatría. 2010;72(5):309-16

Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M.J, et al.  European guidelines on the management of hypertension: The European Society of Hypertension position statement (2009). Nadcisnienie Tetnicze. 2010;14(1):1-47

Medina Polo J, Domínguez Esteban M, Morales JM, Pamplona M, Andrés A, Jiménez C, et al. Cardiovascular events after simultaneous pancreas-kidney transplantation. Transplant Proc. 2010;42(8):2981-3

Morales JM, Campistol JM, Domínguez Gil B, Andrés A, Esforzado N, Oppenheimer F, et al. Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant. 2010;10(11):2453-62.

Morales E, Gutiérrez E, Andrés A. Treatment with calcimimetics in kidney transplantation. Transplant Rev (Orlando). 2010;24(2):79-88.

Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697-704.

Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77(11):956-61.

Praga M, Morales E. Obesity-related renal damage: changing diet to avoid progression. Kidney Int. 2010;78(7):633-5.

Praga Terente M. Insuficiencia renal crónica en pacientes con diabetes tipo 2. Med Clin (Barc). 2010;134(8):353-4

Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo Jr. JL, Katayama S, et al. Erratum: Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetología. 2010;53(1):49-57. Erratum in: Diabetologoia. 2010;53(2):397

Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo Jr. JL, Katayama S, et al. Erratum: Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetología. 2010;53(2):397. Erratum for: Diabetologoia. 2010;53(1):49-57

Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255-66.

Ruilope L, Izzo J, Haller H, Waeber B, Oparil S, Weber M, et al. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know? J Clin Hypertens (Greenwich). 2010;12(6):422-30.

Ruilope LM, Segura J. ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendations. Expert Opin Pharmacother. 2010;11(16):2619-23

Segura J, Gorostidi M. – Evidencias generadas por el proyecto CARDIORISC. Hipertens Riesgo Vasc. 2010;27(Supl 1):4-8

Segura J, De la Sierra A, Ruilope LM. Detection and treatment of resistant hypertension. Curr Hypertens Rep. 2010;12(5):325-30.

Segura de la Morena J, García Donaire JA, Ruilope Urioste LM. Nuevas estrategias terapéuticas para mejorar el control de la hipertensión arterial y simplificar la pauta de tratamiento farmacológico. Med Clin (Barc). 2010;134(14):635-42.